Origin Biosciences clinical trials
A subsidiary of BridgeBio
The registry lists 5 studies whose lead sponsor is Origin Biosciences. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 17, 2023.
Status
- Completed
- 5
Registry sponsor names on this page
- Origin Biosciences5 studies
Something wrong with this grouping? Tell us on the BridgeBio page.
Studies
Recruiting first, then most recently updated. Showing 5 of 5. All BridgeBio studies →
- Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type ACompletedNCT02629393Phase 2/3
Sponsor listed in the registry: Origin Biosciences
- Safety & Efficacy Study of ORGN001 (Formerly ALXN1101) in Pediatric Patients With MoCD Type A Currently Treated With rcPMPCompletedNCT02047461Phase 2
Sponsor listed in the registry: Origin Biosciences
- Phase 1 Single Dose Study of ALXN1101 in Healthy VolunteersCompletedNCT01894165Phase 1
Sponsor listed in the registry: Origin Biosciences
- A Retrospective, Observational, Noninterventional Data Collection Study for Patients With Molybdenum Cofactor Deficiency Who Have Been Previously Treated With Cyclic Pyranopterin Monophosphate (cPMP)CompletedNCT01640717
Sponsor listed in the registry: Origin Biosciences
- A Natural History Study of Molybdenum Cofactor and Isolated Sulfite Oxidase DeficienciesCompletedNCT01735188
Sponsor listed in the registry: Origin Biosciences